Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T15:36:37.270Z.
Calculation as of: 2026-10-06T15:36:37.270Z.
Quote observation: 2026-10-06T15:35:07.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 31946573a42b73cd13b381604bc2f467f5098c78190e00cee0d2639f3054c777
PEG RATIO
N/A
4D Molecular Therapeutics, Inc.
Market Cap
$676.45M
PEG Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$701.53M
PEG Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PEG RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| 4D Molecular Therapeutics, Inc. (FDMT) | $676.45M | N/A | N/A | N/A | N/A |
| Helus Pharma Inc. (HELP)vs › | $684.61M | N/A | N/A | N/A | N/A |
| MiMedx Group, Inc. (MDXG)vs › | $670.12M | N/A | N/A | N/A | N/A |
| Annexon, Inc. (ANNX)vs › | $691.42M | N/A | N/A | N/A | N/A |
| OmniAb, Inc. (OABI)vs › | $645.85M | N/A | N/A | N/A | N/A |
| Anteris Technologies Global Corp. (AVR)vs › | $701.53M | N/A | N/A | N/A | N/A |
| Aura Biosciences, Inc. (AURA)vs › | $645.84M | N/A | N/A | N/A | N/A |
| Climb Bio, Inc. (CLYM)vs › | $640.40M | N/A | N/A | N/A | N/A |
| Olema Pharmaceuticals, Inc. (OLMA)vs › | $713.63M | N/A | N/A | N/A | N/A |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $722.58M | 1.00 | 1.06 | 1.06 | 1.06 |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute